mRNA Neoantigen Cancer Vaccine XH001 clinical trials
How each study uses mRNA Neoantigen Cancer Vaccine XH001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the mRNA Neoantigen Cancer Vaccine XH001 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 4
Peking Union Medical College Hospital (1) · Shenzhen Xinhe Biomedical (1) · Jia Wei (1) · Beijing GoBroad Hospital (1) · jianming xu (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test mRNA Neoantigen Cancer Vaccine XH001.
Studies
Open first, then newest update. How each study uses mRNA Neoantigen Cancer Vaccine XH001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid TumorsRecruitingPhase 1Shenzhen Xinhe BiomedicalNCT07594964Written as XH001 Injection
- Clinical Trial on the Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastric CancerRecruitingPhase 1Jia WeiNCT07298200Written as XH001 Injection
- Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal CancerRecruitingPhase 1Beijing GoBroad HospitalNCT07329894Written as XH001 injection
- XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic CancerNot yet recruitingNot applicablePeking Union Medical College HospitalNCT07114666Written as XH001
- A Safety and Efficacy Study of XH001 Combined With Sintilimab Injection in Advanced Solid TumorsRecruitingNot applicablejianming xuNCT05940181Written as XH001+ sintilimab